Faster Drug Approvals Possible as AI Speeds FDA Reviews

Artificial intelligence should speed up the decade-long process to bring new drugs to the market as the nation’s top regulators explore methods for automating portions of its reviews.

While the FDA is the shortest leg in the drug review process, regulators are considering the same AI tools that drug and technology companies are using to improve molecule screenings and clinical trials, Sean Khozin, associate director of the Food and Drug Administration’s Oncology Center of Excellence, said.

“Absolutely, drugs can get onto the market much faster” with artificial intelligence, Khozin said. “We have to quantify the risk and we have to ...